eShowcase: Oracle Remote Data Capture Onsite
New data entry interface runs on top of existing software for accelerated navigation
New data entry interface runs on top of existing software for accelerated navigation
Oracle Corp. (Redwood Shores, CA) introduced Remote Data Capture Onsite, its next-generation EDC system data collection for clinical trial investigative sites. The interface is designed to accelerate and simplify the collection of clinical data and EDC deployment at investigative sites.
The new Oracle interface runs on top of its existing software product Oracle Remote Data Capture v4.5.1 for more intuitive data entry and navigation of CRFs. The interface allows site personnel to easily locate and update patient information and data entry, as well as add pages to the CRF. The system performs immediate online edit checks, which involves a discrepancy management module from the CRF to capture, route, and resolve discrepancies if applicable.
The Onsite interface features graphic icons that illustrate the status of CRF data. It also enables electronic messaging between users, CRF verifications as a group or individually, and backup approvals with e-signatures.
Oracle Corp., (650) 506-8920, www.oracle.com
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Study Finds Many Randomized Clinical Trials Have Poorly Justified Exclusion Criteria
January 21st 2025Investigators find that most exclusion criteria in critical care randomized clinical trials are justifiable, but 60% include at least one poorly justified exclusion, most commonly affecting pregnant or lactating individuals.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
